Fulgent Genetics Shares Plunge on Wider 4Q Loss, FY Outlook Miss

Dow Jones
02/27
 

By Amira McKee

 

Shares of Fulgent Genetics tumbled after the company recorded a wider net loss in the fourth quarter and guided for lower-than-expected results in 2026.

The stock plunged 32% to $16.84 in Friday morning trading. The shares have gained 7.9% in the past year.

The medical services company recorded a fourth-quarter net loss of $23.4 million, or 76 cents a share, compared with a loss of $5.9 million, or 19 cents a share, a year earlier.

Adjusted earnings came in at 16 cents a share, beating the 3 cents that Wall Street was expecting, according to FactSet.

Revenue grew 9% to $83.3 million, missing the $85.4 million that analysts polled by FactSet were looking for.

For 2026, Fulgent expects to log a full-year adjusted loss per share of around $1.45 on revenue of around $350.0 million. Wall Street is forecasting an adjusted loss of 32 cents a share on revenue of $356.3 million for the full year.

 

Write to Amira McKee at amira.mckee@wsj.com

 

(END) Dow Jones Newswires

February 27, 2026 10:17 ET (15:17 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.

应版权方要求,你需要登录查看该内容

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10